MedTrace Logo

An Additional Study of NPC-22 in Healthy Adult Males

NCT04503863 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-02-07

No results posted yet for this study

Summary

The purpose of this study is to examine the safety and pharmacokinetics of high dose NPC-22 administration in healthy adult males.

The effect of administration routes for pharmacokinetics will be examined in advance.

Conditions

  • Safety and Pharmacokinetics

Interventions

DRUG

NPC-22

Single administration of middle dose NPC-22

DRUG

NPC-22

Single administration of high dose NPC-22

DRUG

NPC-22 Placebo

Single administration of NPC-22 Placebo

Sponsors & Collaborators

  • Nobelpharma

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2020-11-06
Completion
2021-12-28

Countries

  • Japan

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04503863 on ClinicalTrials.gov